Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Dermatologic 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 4Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Recurrence 1Precancerous Conditions 1Papillomavirus Infections 1Lung Neoplasms 1Folic Acid Deficiency 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Atypical Squamous Cells of the Cervix 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Folic Acid × Gynecologic × Clear all
NCT01188876 2018-01-19

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Massachusetts General Hospital

Phase 1/2 Completed
50 enrolled 15 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡